Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
Status:
Recruiting
Trial end date:
2023-01-26
Target enrollment:
Participant gender:
Summary
Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the
safety and tolerability, PK, occurrence of ADA, and efficacy of nirsevimab in
immunocompromised children who are ≤ 24 months of age at the time of dose administration.
Approximately 100 subjects will be enrolled. Subjects will be followed for approximately 1
year after dose administration.